Navigation Links
Kendle Experts to Present at the Drug Information Association 44th Annual Meeting
Date:6/19/2008

CINCINNATI, June 19 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading global full-service clinical research organization (CRO), today announced that several of its experts will present at the upcoming Drug Information Association (DIA) 44th Annual Meeting. The meeting is scheduled for June 22-26, 2008, at the Boston Convention and Exhibition Center in Boston, Mass. Kendle's experts will speak on key topics in the clinical development industry, including EDC, biomarkers, regulatory affairs, adaptive clinical trial design, professional development and patient access and retention.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

In addition to attending presentations by Kendle speakers, attendees at the DIA Annual Meeting may visit Kendle experts at two booths in the exhibit hall. Booth 1804 will focus on the company's global Phase I-IV service offerings and will preview its recently expanded Early Phase capabilities following the June 2 acquisition of DecisionLine Clinical Research Corporation, an early phase CRO specializing in the conduct of Phase I studies involving the measurement of pharmacodynamic effects of central nervous system (CNS) drugs. Booth 456 will focus on career opportunities at Kendle.

Kendle speakers include:

June 23

EDC: Faster Horse or Model T?

Sylva Collins, PhD, Vice President, Global Biometrics

10:30 a.m. - 12 p.m.

June 24

Biomarkers and Surrogate Endpoints: Definitions, Background, and

Validation

Lisa Jenkins, PhD, Regulatory Group Leader

8 - 9:30 a.m.

General Process and Best Practices for EOP2 and Pre-NDA Meetings

Lisa Jenkins, PhD, Regulatory Group Leader

10 - 11:30 a.m.

Recent Advances in Adaptive Clinical Trial Designs

Lisa Jenkins, PhD, Regulatory Group Leader

2 - 3:30 p.m.

June 25

Marketing Yourself as a Candidate in a Competitive Clinical Research Job

Market

Bill Neese, MBA, Director, Global Recruitment

10:30 a.m. - 12 p.m.

June 26

Global Patient Recruitment and Retention: Identifying and Overcoming

Barriers to Accelerate Patient Recruitment and Retention Worldwide

Janet Jones, PhD, Senior Director, Strategic Patient Access

8:30 - 10 a.m.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com .
Available Topic Expert(s): For information on the listed expert(s), click appropriate link. William L Wherle https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=26220


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Promise of Vicals CMV Vaccine Noted by Independent Experts
2. Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows
3. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
4. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
5. Health Experts and Families Encourage Annual Childhood Flu Vaccination to Reduce Flu-Related Illnesses and Deaths in Children
6. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
7. Seriously Low Vaccination Rates Cause Experts to Call for Increased Immunization Before Influenza Season Peaks
8. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
9. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
10. Oridion Announces Major Medical Research and Congress Presentations
11. Nventa to Present at Bio 2008 International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... York City-based market research firm Kalorama Information notes seven trends ... new products to new costs, to the threat of generic ... Potential Pipeline Disruptors . Among them are ... Age-Driven Growth - True Impact Moment Arriving   ... growing population and, to a more extreme extent, the aging ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
Breaking Medicine Technology:
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 (the ... adipose filtration technology. The '398 and '324 patents cover methods and systems ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... focused on delivering end-to-end sleep health care at scale, indicates record-breaking adherence ... that adherence rates for positive airway pressure (PAP) therapy, the most widely utilized ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
Breaking Medicine News(10 mins):